Nurix Therapeutics Q3 swings to profit on Roche collaboration
NRIX•Nurix Therapeutics reported Q3 revenue of $673.06 million and net income of $549.81 million, with diluted EPS of $4.73. The company ended the quarter with $1.1 billion in cash and expects its runway to extend into the second half of 2029.
1. Quarterly results
Nurix Therapeutics swung to a Q3 profit, reporting net income of $549.81 million and diluted EPS of $4.73. Revenue was $673.06 million, driven mainly by Roche license revenue and a Sanofi milestone payment.
2. Cash and development plans
The company ended Q3 with $1.1 billion in cash and expects its cash runway to extend into the second half of 2029. Nurix plans to expand bexobrutideg development into immune-mediated diseases, including CSU and MS, and enroll about 30 patients per tumor type in NX-1607 expansion cohorts.
